Project information
FANTOM Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance (FANTOM)

Project Identification
Project Period
1/2023 - 12/2026
Investor / Pogramme / Project type
European Union
MU Faculty or unit
Faculty of Medicine
Cooperating Organization
Technical University Munich
University of Cambridge
Universita degli Studi di Padova
Medizinische Universitaet Wien
The University of Turin
University of Milano
University Hospital Hamburg-Eppendorf

The FANTOM Doctoral Network (DN) composed of 8 beneficiaries and 13 associated partners in 6 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.

Sustainable Development Goals

Masaryk University is committed to the UN Sustainable Development Goals, which aim to improve the conditions and quality of life on our planet by 2030.

Sustainable Development Goal No.  3 – Good health and well-being Sustainable Development Goal No.  4 – Quality education Sustainable Development Goal No.  5 – Gender equality Sustainable Development Goal No.  8 – Decent work and economic growth Sustainable Development Goal No.  10 – Reduced inequalities Sustainable Development Goal No.  17 – Partnerships for the goals


Total number of publications: 1

You are running an old browser version. We recommend updating your browser to its latest version.

More info